PRZEWLEKŁA CHOROBA NEREK ORAZ WYBRANE ASPEKTY MONITOROWANIA STANU BIORCÓW NERKI

Natalia Korytowska; Beata Pytlak; Mariusz Niemczyk

doi:10.56782/pps.14

Published : 2020-08-07

Vol. 18 No. 4 (2020)

CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING

Natalia Korytowska

Beata Pytlak

Mariusz Niemczyk

DOI: https://doi.org/10.56782/pps.14

Abstract

Kidney diseases are an important challenge for nowadays medicine. Chronic kidney disease is classified as a “disease of affluence”, moreover the problem of kidney diseases is also increasing due to an aging of a population. Elderly people are a part of a population with high risk of kidney failure. Additionally, an occurrence of concomitant diseases, e.g. cardiovascular diseases, significantly hinders treatment and increases mortality in this group. Chronic kidney disease is progressive and finally leads to end-stage renal disease. In that case a life-saving method is renal replacement therapy – dialysis or kidney transplantation. Due to limited number of organs for transplantation, majority of patients with end-stage renal disease are treated with dialysis. Kidney transplantation is an optimal method of renal replacement therapy, because of the longest survival of patients, the best quality of life and because it is less expensive than dialysis. Monitoring of transplanted kidneys function aims to provide a long life of “new” organ. Early diagnosis of unsatisfactory graft function and rapid medical intervention is intended to prevent the loss of the transplanted organ. Monitoring of parameters such as eGFR, a concentration of immunosuppressive drugs or level of markers of cardiovascular diseases is an important part of treatment.

Keywords:

cardiovascular markers, chronic kidney disease, kidney transplantation, monitoring

Similar Articles

Kinga Kocur, Katarzyna Camlet, Anna Ziobro, Mateusz Ziomek, Wojciech Kaźmierski, Paulina Lis, Jakub Jurek, Anna Lis, Renaissance of Ketamine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Iwona Lewandowska Lewandowska, Monika Zielińska-Pisklak, Łukasz Szeleszczuk, Dariusz Maciej Pisklak, Marcin Sobczak, PULMONARY HYPERTENSION — PATHOPHYSIOLOGY AND DRUGS USED IN THERAPY , Prospects in Pharmaceutical Sciences: Vol. 18 No. 2 (2020)
Maciej Stępień, Stanisław Anczyk, Cytokine-targeted treatment in alopecia areata - new possibilities? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The glucagon-like peptide-1 analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
Natalia Cichoń, Dominika Lach, Joanna Saluk-Bijak, Michał Bijak, ANTICOAGULANT THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 15 No. 5 (2017)
Szymon Barczak, Barbara Badura, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało, Severe course of HIV-related Kaposi’s sarcoma with cutaneous, visceral and oral manifestations in a late-presenting patient , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Martyna Chechłacz, Natalia Korytowska, COMPOUNDS THAT BIND TO PLASMA PROTEINS IN HUMANS. SIGNIFICANCE IN THERAPY AND METHODS FOR QUANTIFICATION OF A FREE FRACTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 6 (2017)
Karolina Nowakowska, EPIDEMIOLOGY, CLASSIFICATION AND DIAGNOSIS OF FUNCTIONING AND NONFUNCTIONING PITUITARY ADENOMAS , Prospects in Pharmaceutical Sciences: Vol. 13 No. 6 (2015)
Bartłomiej Kałaska, Joanna Mikłosz, Emilia Sokołowska, Andrzej Mogielnicki, THE PROS AND CONS OF MODERN ANTICOAGULANT THERAPY , Prospects in Pharmaceutical Sciences: Vol. 14 No. 10 (2016)

<< < 1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Korytowska, N., Pytlak, B., & Niemczyk, M. (2020). CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING. Prospects in Pharmaceutical Sciences, 18(4), 27–39. https://doi.org/10.56782/pps.14

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3, 1–150.

Ekser, B.; Cooper, D.K.; Tector, A.J. The need for xenotransplantation as a source of organs and cells for clinical transplantation. Int J Surg 2015, 23, 199-204, doi:10.1016/j.ijsu.2015.06.066. DOI: https://doi.org/10.1016/j.ijsu.2015.06.066

Ślubowska, K.; Durlik, M. Czynniki ryzyka sercowo-naczyniowego u biorców przeszczepu nerki. Forum Nefrol 2014, 7, 241–248

Hruby, Z. Nefrologia praktyczna; PZWL: Warszawa, 2001.

Szczeklik, A. Choroby wewnętrzne. Tom II; Medycyna praktyczna: Kraków, 2006.

Dębska-Ślizień, A.; Rutkowski, B.; Rutkowski, P.; Korejwo, G.; Gellert, R. Condition of renal replacement therapy in Poland-2016. 2018, 22, 1-8

Alsaad, K.O.; Herzenberg, A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007, 60, 18-26, doi:10.1136/jcp.2005.035592. DOI: https://doi.org/10.1136/jcp.2005.035592

Rodriguez-Iturbe, B.; Haas, M. Streptococcus pyogenes: Basic biology to clinical manifestations. Post-streptococcal glomerulonephritis; University of Oklahoma Health Sciences Center, Oklahoma City,: 2016.

Boils, C.L.; Nasr, S.H.; Walker, P.D.; Couser, W.G.; Larsen, C.P. Update on endocarditis-associated glomerulonephritis. Kidney Int 2015, 87, 1241-1249, doi:10.1038/ki.2014.424. DOI: https://doi.org/10.1038/ki.2014.424

Molina, M.; Sánchez, J.; Sevillano, Á.; Bengoa, I.; Gutiérrez, E.; Martínez, M.A.; Hernández, E.; Praga, M. Two cases of glomerulonephritis in one patient infected with the hepatitis C virus. Nefrologia 2013, 33, 593-600, doi:10.3265/Nefrologia.pre2013.May.12067.

Zand, L.; Fervenza, F.C.; Nasr, S.H.; Sethi, S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014, 27, 165-171, doi:10.1007/s40620-014-0049-0. DOI: https://doi.org/10.1007/s40620-014-0049-0

Liu, M.; Li, X.C.; Lu, L.; Cao, Y.; Sun, R.R.; Chen, S.; Zhang, P.Y. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 2014, 18, 2918-2926.

Ronco, C.; McCullough, P.; Anker, S.D.; Anand, I.; Aspromonte, N.; Bagshaw, S.M.; Bellomo, R.; Berl, T.; Bobek, I.; Cruz, D.N., et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010, 31, 703-711, doi:10.1093/eurheartj/ehp507. DOI: https://doi.org/10.1093/eurheartj/ehp507

Tonelli, M.; Wiebe, N.; Culleton, B.; House, A.; Rabbat, C.; Fok, M.; McAlister, F.; Garg, A.X. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17, 2034-2047, doi:10.1681/asn.2005101085. DOI: https://doi.org/10.1681/ASN.2005101085

Subbiah, A.K.; Chhabra, Y.K.; Mahajan, S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia 2016, 8, 56-61, doi:10.1136/heartasia-2016-010809. DOI: https://doi.org/10.1136/heartasia-2016-010809

Manjunath, G.; Tighiouart, H.; Coresh, J.; Macleod, B.; Salem, D.N.; Griffith, J.L.; Levey, A.S.; Sarnak, M.J. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63, 1121-1129, doi:10.1046/j.1523-1755.2003.00838.x. DOI: https://doi.org/10.1046/j.1523-1755.2003.00838.x

Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif 2015, 39, 84-92, doi:10.1159/000368940. DOI: https://doi.org/10.1159/000368940

Reddy, Y.S.; Kiranmayi, V.S.; Bitla, A.R.; Krishna, G.S.; Rao, P.V.; Sivakumar, V. Nitric oxide status in patients with chronic kidney disease. Indian J Nephrol 2015, 25, 287-291, doi:10.4103/0971-4065.147376. DOI: https://doi.org/10.4103/0971-4065.147376

De Gennaro Colonna, V.; Bianchi, M.; Pascale, V.; Ferrario, P.; Morelli, F.; Pascale, W.; Tomasoni, L.; Turiel, M. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009, 15, 91-101.

Förstermann, U.; Sessa, W.C. Nitric oxide synthases: regulation and function. Eur Heart J 2012, 33, 829-837, doi:10.1093/eurheartj/ehr304. DOI: https://doi.org/10.1093/eurheartj/ehr304

Crichton, R.R.; Wilmet, S.; Legssyer, R.; Ward, R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002, 91, 9-18, doi:10.1016/s0162-0134(02)00461-0. DOI: https://doi.org/10.1016/S0162-0134(02)00461-0

Modi, G.K.; Naik, N. Atherosclerosis in chronic kidney disease: Striking while the Iron is labile. Indian J Nephrol 2013, 23, 337-339.

Cornelissen, A.; Guo, L.; Sakamoto, A.; Virmani, R.; Finn, A.V. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine 2019, 47, 598-606, doi:10.1016/j.ebiom.2019.08.014. DOI: https://doi.org/10.1016/j.ebiom.2019.08.014

Palit, S.; Kendrick, J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des 2014, 20, 5829-5833. DOI: https://doi.org/10.2174/1381612820666140212194926

Schlieper, G.; Schurgers, L.; Brandenburg, V.; Reutelingsperger, C.; Floege, J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016, 31, 31-39,doi:10.1093/ndt/gfv111. DOI: https://doi.org/10.1093/ndt/gfv111

Sinnakirouchenan, R.; Holley, J.L. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis 2011, 18, 428-432, doi:10.1053/j.ackd.2011.09.001. DOI: https://doi.org/10.1053/j.ackd.2011.09.001

Yang, F.; Khin, L.W.; Lau, T.; Chua, H.R.; Vathsala, A.; Lee, E.; Luo, N. Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease. PLoS One 2015, 10, e0140195, doi:10.1371/journal.pone.0140195. DOI: https://doi.org/10.1371/journal.pone.0140195

Weir, M.R.; Burgess, E.D.; Cooper, J.E.; Fenves, A.Z.; Goldsmith, D.; McKay, D.; Mehrotra, A.; Mitsnefes, M.M.; Sica, D.A.; Taler, S.J. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 2015, 26, 1248-1260, doi:10.1681/asn.2014080834. DOI: https://doi.org/10.1681/ASN.2014080834

Kraus, M.A.; Kansal, S.; Copland, M.; Komenda, P.; Weinhandl, E.D.; Bakris, G.L.; Chan, C.T.; Fluck, R.J.; Burkart, J.M. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis 2016, 68, S51-S58, doi:10.1053/j.ajkd.2016.05.020. DOI: https://doi.org/10.1053/j.ajkd.2016.05.020

Vikrant, S.; Guleria, R.C.; Kanga, A.; Verma, B.S.; Singh, D.; Dheer, S.K. Microbiological aspects of peritonitis in patients on continuous ambulatory peritoneal dialysis. Indian J Nephrol 2013, 23, 12-17, doi:10.4103/0971-4065.107188. DOI: https://doi.org/10.4103/0971-4065.107188

O'Connor, N.R.; Kumar, P. Conservative Management of End-Stage Renal Disease without Dialysis: A Systematic Review. Journal of Palliative Medicine 2012, 15, 228-235, doi:10.1089/jpm.2011.0207. DOI: https://doi.org/10.1089/jpm.2011.0207

Gętek, M.; Nowakowska- Zajdel, E. Quality of life of patients on dialysis and after renal transplantation. Ann Acad Med Siles 2010, 64, 23-30.

Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji "Poltransplant". 2018;1. www. poltransplant.pl/Download/Biuletyn_2018.pdf ( 21.08.2020).

Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji " Poltransplant ". 2020;1. www.poltransplant.pl/Download/Biuletyn2020.pdf (10.10.2020).

Gołąb, J.; Jakóbisiak, M.; Lasek, W.; Stokłosa, T. Immunologia; Towarzystwo Naukowe PWN: Warszawa, 2012.

Moreau, A.; Varey, E.; Anegon, I.; Cuturi, M.C. Effector mechanisms of rejection. Cold Spring Harb Perspect Med 2013, 3, a015461, doi:10.1101/cshperspect.a015461. DOI: https://doi.org/10.1101/cshperspect.a015461

Bhatti, A.B.; Usman, M. Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. Cureus 2015, 7, e376, doi:10.7759/cureus.376. DOI: https://doi.org/10.7759/cureus.376

Ghods, A.J. Living kidney donation: the outcomes for donors. Int J Organ Transplant Med 2010, 1, 63-71.

BTS/RA. Living Donor Kidney Transplantation Guidelines 2018 www.bts .org.uk.

KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation 2017, 101, 1–109.

Abramowicz, D.; Cochat, P.; Claas, F.H.; Heemann, U.; Pascual, J.; Dudley, C.; Harden, P.; Hourmant, M.; Maggiore, U.; Salvadori, M., et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant 2015, 30, 1790-1797, doi:10.1093/ndt/gfu216. DOI: https://doi.org/10.1093/ndt/gfu216

Alelign, T.; Ahmed, M.M.; Bobosha, K.; Tadesse, Y.; Howe, R.; Petros, B. Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. J Immunol Res 2018, 2018, 1-18, doi:10.1155/2018/5986740. DOI: https://doi.org/10.1155/2018/5986740

Stoumpos, S.; Jardine, A.G.; Mark, P.B. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int 2015, 28, 10-21, doi:10.1111/tri.12413. DOI: https://doi.org/10.1111/tri.12413

Durlik; M.; K., Z. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. Fundacja Zjednoczeni dla Transplantacji: Warszawa 2016

KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, Suppl 3, S1-155, doi:10.1111/j.1600-6143.2009.02834.x. DOI: https://doi.org/10.1111/j.1600-6143.2009.02834.x

van Sandwijk, M.S.; Bemelman, F.J.; Ten Berge, I.J. Immunosuppressive drugs after solid organ transplantation. Neth J Med 2013, 71, 281-289.

Muntean, A.; Lucan, M. Immunosuppression in kidney transplantation. Clujul Med 2013, 86, 177-180.

Wagner, M.; Earley, A.K.; Webster, A.C.; Schmid, C.H.; Balk, E.M.; Uhlig, K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2015, CD007746, doi:10.1002/14651858.CD007746.pub2. DOI: https://doi.org/10.1002/14651858.CD007746.pub2

Friedewald, J.J.; Reese, P.P. The kidney-first initiative: what is the current status of preemptive transplantation? Adv Chronic Kidney Dis 2012, 19, 252-256, doi:10.1053/j.ackd.2012.05.001. DOI: https://doi.org/10.1053/j.ackd.2012.05.001

Rambod, M.; Shabani, M.; Shokrpour, N.; Rafii, F.; Mohammadalliha, J. Quality of life of hemodialysis and renal transplantation patients. Health Care Manag (Frederick) 2011, 30, 23-28, doi:10.1097/HCM.0b013e3182078ab6. DOI: https://doi.org/10.1097/HCM.0b013e3182078ab6

Singh, S.K.; Cole, E.H.; Kim, S.J. Delayed Graft Function and Kidney Transplantation. In Kidney Transplantation, Weir, M., Lerma, E., Eds. Springer, New York, NY: Kidney Transplantation, 2014. DOI: https://doi.org/10.1007/978-1-4939-0342-9_13

Florkowski, C.M.; Chew-Harris, J.S. Methods of Estimating GFR - Different Equations Including CKD-EPI. Clin Biochem Rev 2011, 32, 75-79.

Bartlomiejczyk, I.; Zochowska, D.; Sanko-Resmer, J.; Matuszewicz, D.; Paczek, L. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. Transplant Proc 2006, 38, 94-96, doi:10.1016/j.transproceed.2005.12.042. DOI: https://doi.org/10.1016/j.transproceed.2005.12.042

Mohammadpour, N.; Elyasi, S.; Vahdati, N.; Mohammadpour, A.H.; Shamsara, J. A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 2011, 14, 485-498.

Dasgupta, A.; Khalil, S.A.; Johnson-Davis, K.L. Analytical Performance Evaluation of a New Cobas Tacrolimus Assay on Cobas e411 Analyzer: Comparison of Values Obtained by the CMIA

Tacrolimus Assay and a Liquid Chromatography Combined with Tandem Mass Spectrometric Method. Ann Clin Lab Sci 2016, 46, 204-208.

Morgan, P.E.; Brown, N.W.; Tredger, J.M. A direct method for the measurement of everolimus and sirolimus in whole blood by LCMS/MS using an isotopic everolimus internal standard. Ther Drug Monit 2014, 36, 358-365, doi:10.1097/FTD.0000000000000006. DOI: https://doi.org/10.1097/FTD.0000000000000006

Cravedi, P.; Heeger, P.S. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012, 17, 26-32, doi:10.1097/MOT.0b013e32834ee402. DOI: https://doi.org/10.1097/MOT.0b013e32834ee402

Townamchai, N.; Safa, K.; Chandraker, A. Immunologic monitoring in kidney transplant recipients. Kidney Res Clin Pract 2013, 32, 52-61, doi:10.1016/j.krcp.2013.04.002. DOI: https://doi.org/10.1016/j.krcp.2013.04.002

Bojanowska, M.; Białobrzeska, B. Native and transplanted kidney biopsy — holistic nursing care. Forum Nefrol 2010, 3, 317–325

Sawosz, M.; Bączkowska, T. Protocol biopsies of a transplanted kidney. 2012, 5 105–109

Tapia-Canelas, C.; Zometa, R.; López-Oliva, M.O.; Jiménez, C.; Rivas, B.; Escuin, F.; Yébenes, L.; Selgas, R. Complications associated with renal graft biopsy in transplant patients. Nefrologia 2014, 34, 115-119, doi:10.3265/Nefrologia.pre2013.Nov.12232.

Rao, N.N.; Coates, P.T. Cardiovascular Disease After Kidney Transplant. Semin Nephrol 2018, 38, 291-297, doi:10.1016/j.semnephrol.2018.02.008. DOI: https://doi.org/10.1016/j.semnephrol.2018.02.008

Alani, H.; Tamimi, A.; Tamimi, N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014, 3, 156-168, doi:10.5527/wjn.v3.i4.156. DOI: https://doi.org/10.5527/wjn.v3.i4.156

Dosi, R.; Bhatt, N.; Shah, P.; Patell, R. Cardiovascular disease and menopause. J Clin Diagn Res 2014, 8, 62-64, doi:10.7860/JCDR/2014/6457.4009. DOI: https://doi.org/10.7860/JCDR/2014/6457.4009

Kolber, M.R.; Scrimshaw, C. Family history of cardiovascular disease. Can Fam Physician 2014, 60, 1016.

Muntner, P.; He, J.; Astor, B.C.; Folsom, A.R.; Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16, 529-538, doi:10.1681/ASN.2004080656. DOI: https://doi.org/10.1681/ASN.2004080656

Vlagopoulos, P.T.; Sarnak, M.J. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005, 89, 587-611, doi:10.1016/j.mcna.2004.11.003. DOI: https://doi.org/10.1016/j.mcna.2004.11.003

Romero, J.R.; Morris, J.; Pikula, A. Stroke prevention: modifying risk factors. Therapeutic advances in cardiovascular disease 2008, 2, 287-303, doi:10.1177/1753944708093847. DOI: https://doi.org/10.1177/1753944708093847

Collins, P. Risk factors for cardiovascular disease and hormone therapy in women. Heart 2006, 92 Suppl 3, iii24-28, doi:10.1136/hrt.2005.071787. DOI: https://doi.org/10.1136/hrt.2005.071787

Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Collaboration, P.S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903-1913. DOI: https://doi.org/10.1016/S0140-6736(02)11911-8

Aronow, W.S. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012, 2, 160-170.

Schnohr, P.; Lange, P.; Scharling, H.; Jensen, J.S. Long-term physical activity in leisure time and mortality from coronary heart disease, stroke, respiratory diseases, and cancer. The Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 2006, 13, 173-179, doi:10.1097/01.hjr.0000198923.80555.b7. DOI: https://doi.org/10.1097/01.hjr.0000198923.80555.b7

Hap, K.; Madziarska, K.; Hap, W.; Mazanowska, O. Phenotypic risk factors for new-onset diabetes mellitus (NODAT) in renal transplant recipients. Postepy Hig Med Dosw (Online) 2014, 68, 1347-1351, doi:10.5604/17322693.1129186. DOI: https://doi.org/10.5604/17322693.1129186

Murchison, L.E. Hyperlipidaemia. Br Med J (Clin Res Ed) 1985, 290, 535-538. DOI: https://doi.org/10.1136/bmj.290.6467.535

Nelson, R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013, 40, 195-211, doi:10.1016/j.pop.2012.11.003. DOI: https://doi.org/10.1016/j.pop.2012.11.003

Rafieian-Kopaei, M.; Setorki, M.; Doudi, M.; Baradaran, A.; Nasri, H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014, 5, 927-946.

Fischer, S.; Schatz, U.; Julius, U. Practical recommendations for the management of hyperlipidemia. Atheroscler Suppl 2015, 18, 194-198, doi:10.1016/j.atherosclerosissup.2015.02.029. DOI: https://doi.org/10.1016/j.atherosclerosissup.2015.02.029

Messner, B.; Bernhard, D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014, 34, 509-515, doi:10.1161/ATVBAHA.113.300156. DOI: https://doi.org/10.1161/ATVBAHA.113.300156

Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364, 937-952, doi:10.1016/S0140-6736(04)17018-9. DOI: https://doi.org/10.1016/S0140-6736(04)17018-9

Neale, J.; Smith, A.C. Cardiovascular risk factors following renal transplant. World J Transplant 2015, 5, 183-195, doi:10.5500/wjt.v5.i4.183. DOI: https://doi.org/10.5500/wjt.v5.i4.183

Kokkinos, P. Physical activity, health benefits, and mortality risk. ISRN Cardiol 2012, 2012, 718789, doi:10.5402/2012/718789. DOI: https://doi.org/10.5402/2012/718789

Klop, B.; Elte, J.W.; Cabezas, M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5, 1218-1240, doi:10.3390/nu5041218. DOI: https://doi.org/10.3390/nu5041218

Kubota, Y.; Evenson, K.R.; MacLehose, R.F.; Roetker, N.S.; Joshu, C.E.; Folsom, A.R. Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer. Med Sci Sports Exerc 2017, 8, 1599–1605, doi:10.1249/MSS.0000000000001274. DOI: https://doi.org/10.1249/MSS.0000000000001274

Romano, G.; Lorenzon, E.; Montanaro, D. Effects of exercise in renal transplant recipients. World J Transplant 2012, 2, 46-50, doi:10.5500/wjt.v2.i4.46. DOI: https://doi.org/10.5500/wjt.v2.i4.46

Orlandi, G.; Sofi, F.; Moscarelli, L.; Cirami, L.; Mancini, S.; Stefani, L. Exercise Prescription in Renal Transplant Recipients: From Sports Medicine Toward Multidisciplinary Aspects: A Pilot Study. J. Funct. Morphol. Kinesiol. 2020, 5, 10, doi:https://doi.org/10.3390/jfmk5010010. DOI: https://doi.org/10.3390/jfmk5010010

Ferguson, B. ACSM’s Guidelines for Exercise Testing and Prescription 9th Ed. 2014. The Journal of the Canadian Chiropractic Association 2014, 58, 328-328.

Małgorzewicz, S.; Ciechanowski, K.; Kozłowska, L.; Krzanowska, K.; Krzanowski, M.; Kaczkan, M.; Borek, P.; Jankowska, M.; Rutkowski, B.; Dębska-Ślizień, A. Nutrition recommendations in chronic kidney disease - the position of the working group of the Polish Nephrological Society. Forum Nefrologiczne 2019, 12, 240–278.

Currie, G.; Delles, C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2013, 7, 13-24, doi:10.2147/IJNRD.S40522. DOI: https://doi.org/10.2147/IJNRD.S40522

Hillege, H.L.; Fidler, V.; Diercks, G.F.; van Gilst, W.H.; de Zeeuw, D.; van Veldhuisen, D.J.; Gans, R.O.; Janssen, W.M.; Grobbee, D.E.; de Jong, P.E., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106, 1777-1782, doi:10.1161/01.cir.0000031732.78052.81. DOI: https://doi.org/10.1161/01.CIR.0000031732.78052.81

Lee, W.H.; Hsu, P.C.; Chu, C.Y.; Lee, H.H.; Lee, M.K.; Lee, C.S.; Yen, H.W.; Lin, T.H.; Voon, W.C.; Lai, W.T., et al. Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation. Int J Med Sci 2015, 12, 618-624, doi:10.7150/ijms.11924. DOI: https://doi.org/10.7150/ijms.11924

Durlik, M. Patogeneza i klinika niedokrwistości u chorych po przeszczepieniu nerki. Forum Nefrol. 2010, 3, 298-304

Karthikeyan, V.; Karpinski, J.; Nair, R.C.; Knoll, G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004, 4, 262-269. DOI: https://doi.org/10.1046/j.1600-6143.2003.00315.x

Hariharan, S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis 2006, 47, S22-36, doi:10.1053/j.ajkd.2005.12.046. DOI: https://doi.org/10.1053/j.ajkd.2005.12.046

Sarnak, M.J.; Tighiouart, H.; Manjunath, G.; MacLeod, B.; Griffith, J.; Salem, D.; Levey, A.S. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002, 40, 27-33. DOI: https://doi.org/10.1016/S0735-1097(02)01938-1

Cervantes Gracia, K.; Llanas-Cornejo, D.; Husi, H. CVD and Oxidative Stress. J Clin Med 2017, 6, 22, doi:10.3390/jcm6020022. DOI: https://doi.org/10.3390/jcm6020022

Tabriziani, H.; Lipkowitz, M.S.; Vuong, N. Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation. Clin Kidney J 2018, 11, 130-135, doi:10.1093/ckj/sfx091. DOI: https://doi.org/10.1093/ckj/sfx091

Sezer, S.; Akcay, A.; Ozdemir, F.N.; Kulah, E.; Arat, Z.; Haberal, M. Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 2004, 18, 722-725, doi:10.1111/j.1399-0012.2004.00286.x. DOI: https://doi.org/10.1111/j.1399-0012.2004.00286.x

Kaptoge, S.; White, I.R.; Thompson, S.G.; Wood, A.M.; Lewington, S.; Lowe, G.D.; Danesh, J.; Collaboration, F.S. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007, 166, 867-879, doi:10.1093/aje/kwm191. DOI: https://doi.org/10.1093/aje/kwm191

Ozdemir, N.F.; Elsurer, R.; Ibis, A.; Arat, Z.; Haberal, M. Serum Creactive protein surge in renal transplant recipients: link with allograft survival. Transplant Proc 2007, 39, 934-937, doi:10.1016/j.transproceed.2007.02.023. DOI: https://doi.org/10.1016/j.transproceed.2007.02.023

Vanholder, R.C.; Eloot, S.; Glorieux, G.L. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis 2016, 67, 664-676, doi:10.1053/j.ajkd.2015.08.029. DOI: https://doi.org/10.1053/j.ajkd.2015.08.029

Vanholder, R.; Van Laecke, S.; Glorieux, G. What is new in uremic toxicity? Pediatr Nephrol 2008, 23, 1211-1221, doi:10.1007/s00467-008-0762-9. DOI: https://doi.org/10.1007/s00467-008-0762-9

Barreto, F.C.; Stinghen, A.E.; de Oliveira, R.B.; Franco, A.T.; Moreno, A.N.; Barreto, D.V.; Pecoits-Filho, R.; Drüeke, T.B.; Massy, Z.A. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol 2014, 36, 221-235. DOI: https://doi.org/10.5935/0101-2800.20140033

Cha, R.H.; Kang, S.W.; Park, C.W.; Cha, D.R.; Na, K.Y.; Kim, S.G.; Yoon, S.A.; Han, S.Y.; Chang, J.H.; Park, S.K., et al. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction. Clin J Am Soc Nephrol 2016, 11, 559-567, doi:10.2215/CJN.12011214. DOI: https://doi.org/10.2215/CJN.12011214

Aldámiz-Echevarría, L.; Andrade, F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012, 13, 11288-11311, doi:10.3390/ijms130911288. DOI: https://doi.org/10.3390/ijms130911288

Valkonen, V.P.; Päivä, H.; Salonen, J.T.; Lakka, T.A.; Lehtimäki, T.; Laakso, J.; Laaksonen, R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358, 2127-2128, doi:10.1016/S0140-6736(01)07184-7. DOI: https://doi.org/10.1016/S0140-6736(01)07184-7

Willeit, P.; Freitag, D.F.; Laukkanen, J.A.; Chowdhury, S.; Gobin, R.; Mayr, M.; Di Angelantonio, E.; Chowdhury, R. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 2015, 4, e001833, doi:10.1161/JAHA.115.001833. DOI: https://doi.org/10.1161/JAHA.115.001833

Zoccali, C.; Bode-Böger, S.; Mallamaci, F.; Benedetto, F.; Tripepi, G.; Malatino, L.; Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frölich, J., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358, 2113-2117. DOI: https://doi.org/10.1016/S0140-6736(01)07217-8

Ravani, P.; Tripepi, G.; Malberti, F.; Testa, S.; Mallamaci, F.; Zoccali, C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16, 2449-2455, doi:10.1681/ASN.2005010076. DOI: https://doi.org/10.1681/ASN.2005010076

Lau, W.L.; Vaziri, N.D. Urea, a true uremic toxin: the empire strikes back. Clin Sci (Lond) 2017, 131, 3-12, doi:10.1042/CS20160203. DOI: https://doi.org/10.1042/CS20160203

Ndrepepa, G. Uric acid and cardiovascular disease. Clin Chim Acta 2018, 484, 150-163, doi:10.1016/j.cca.2018.05.046. DOI: https://doi.org/10.1016/j.cca.2018.05.046

Currò, M.; Gugliandolo, A.; Gangemi, C.; Risitano, R.; Ientile, R.; Caccamo, D. Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res 2014, 39, 1485-1495, doi:10.1007/s11064-014-1338-7. DOI: https://doi.org/10.1007/s11064-014-1338-7

Ye, Z.; Zhang, Q.; Li, Y.; Wang, C.; Zhang, J.; Ma, X.; Peng, H.; Lou, T. High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. Nutrients 2016, 8, 645, doi:10.3390/nu8100645. DOI: https://doi.org/10.3390/nu8100645

Baszczuk, A.; Kopczyński, Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 2014, 68, 579-589, doi:10.5604/17322693.1102340. DOI: https://doi.org/10.5604/17322693.1102340

Ganguly, P.; Alam, S.F. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015, 14, 6, doi:10.1186/1475-2891-14-6. DOI: https://doi.org/10.1186/1475-2891-14-6

van Ballegooijen, A.J.; Reinders, I.; Visser, M.; Brouwer, I.A. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J 2013, 165, 655-664, 664.e651-655, doi:10.1016/j.ahj.2013.02.014. DOI: https://doi.org/10.1016/j.ahj.2013.02.014

Goettsch, C.; Iwata, H.; Aikawa, E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol 2014, 34, 1333-1335, doi:10.1161/ATVBAHA.114.303637. DOI: https://doi.org/10.1161/ATVBAHA.114.303637

Korytowska, N.; Wyczałkowska-Tomasik, A.; Wiśniewska, A.; Pączek, L.; Giebułtowicz, J. Development of the LC-MS/MS method for determining the p-cresol level in plasma. J Pharm Biomed Anal 2019, 167, 149-154, doi:10.1016/j.jpba.2019.01.041. DOI: https://doi.org/10.1016/j.jpba.2019.01.041

Leong, S.C.; Sirich, T.L. Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins (Basel) 2016, 8, 358, doi:10.3390/toxins8120358. DOI: https://doi.org/10.3390/toxins8120358

Gryp, T.; Vanholder, R.; Vaneechoutte, M.; Glorieux, G. p-Cresyl Sulfate. Toxins (Basel) 2017, 9, 52, doi:10.3390/toxins9020052. DOI: https://doi.org/10.3390/toxins9020052

Korytowska, N.; Sankowski, B.; Wyczałkowska-Tomasik, A.; Pączek, L.; Wroczyński, P.; Giebułtowicz, J. The utility of saliva testing in the estimation of uremic toxin levels in serum. Clin Chem Lab Med 2018, 57, 230-237, doi:10.1515/cclm-2018-0087. DOI: https://doi.org/10.1515/cclm-2018-0087

Chiu, C.A.; Lu, L.F.; Yu, T.H.; Hung, W.C.; Chung, F.M.; Tsai, I.T.; Yang, C.Y.; Hsu, C.C.; Lu, Y.C.; Wang, C.P., et al. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 2010, 7, 275-284, doi:10.1900/RDS.2010.7.275. DOI: https://doi.org/10.1900/RDS.2010.7.275

Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; DuGar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.-M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63, doi:10.1038/nature09922. DOI: https://doi.org/10.1038/nature09922

Tang, W.H.; Wang, Z.; Kennedy, D.J.; Wu, Y.; Buffa, J.A.; AgatisaBoyle, B.; Li, X.S.; Levison, B.S.; Hazen, S.L. Gut microbiotadependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015, 116, 448-455, doi:10.1161/CIRCRESAHA.116.305360. DOI: https://doi.org/10.1161/CIRCRESAHA.116.305360

Chou, R.-H.; Chen, C.-Y.; Chen, I.C.; Huang, H.-L.; Lu, Y.-W.; Kuo, C.-S.; Chang, C.-C.; Huang, P.-H.; Chen, J.-W.; Lin, S.-J. Trimethylamine N-Oxide, Circulating Endothelial Progenitor Cells, and Endothelial Function in Patients with Stable Angina. Scientific Reports 2019, 9, 4249, doi:10.1038/s41598-019-40638-y. DOI: https://doi.org/10.1038/s41598-019-40638-y

Natalia Korytowska

natalia.korytowska@wum.edu.pl

Affiliation:

Zakład Bioanalizy i Analizy Leków, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Beata Pytlak

Affiliation:

Zakład Bioanalizy i Analizy Leków, Wydział Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Mariusz Niemczyk

Affiliation:

Klinika Immunologii, Transplantologii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, ul. Nowogrodzka 59, 02-006 Warszawa Poland

CHRONIC KIDNEY DISEASE AND SELECTED ASPECTS OF KIDNEY RECIPIENTS MONITORING

Natalia Korytowska

Beata Pytlak

Mariusz Niemczyk

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Natalia Korytowska

Beata Pytlak

Mariusz Niemczyk